Since the role of GIIA sPLA2 in mortality from COVID-19 has recently been recognized [12], the development of dual inhibitors of GIIA sPLA2 and SARS-CoV-2 Mpro appears to represent an attractive strategy for the development of novel agents to treat COVID-19. This evidence concerns the gene PLA2G2A and COVID-19.